Vendor dossier · Changsha, Hunan
Hunan Aslsen Technology Co., Ltd.
A Changsha supplier with good verification coverage from three services and the least consistent fulfilment in the directory.
Journal grade · ranked 17 of 20
466 reader reports
on the record
Homopeptide has verification from three of the four independent services this market uses, and the analytical picture is decent. The problem is getting the product: of nine orders we placed, two arrived late by more than three weeks, one arrived split across two parcels a fortnight apart, and one never arrived at all and was refunded after five weeks of chasing.
Storefront The company sells directly at homopeptide.net. Visit Homopeptide → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Nine independent purity determinations, mean 96.9%, range 94.6–98.5%. Mid-table, with one result below 95%. Nothing alarming and nothing impressive.
The operational record is the story. Median transit was fourteen days against a quoted seven to ten, with a long tail: the slowest completed order took thirty-nine days. Communication during delays was poor — on the lost order we sent six messages over five weeks before receiving a substantive reply, and the eventual refund was prompt once someone engaged.
The three independent verifications are real and we confirmed them with the services concerned. They speak to material quality, which is fine. They say nothing about whether the material will arrive, which is the risk a buyer here is actually taking.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Nine independent purity determinations, mean 96.9% (range 94.6–98.5%).
- Verification records held by three of the four independent services, confirmed directly with each.
- Median transit fourteen days against a quoted seven to ten; slowest completed order thirty-nine days.
- One order lost entirely and refunded in full after five weeks and six messages.
What we could not verify
- Why fulfilment is so variable — asked twice; attributed to "logistics partners" without detail.
- Whether the company holds stock or synthesises to order.
- Sterility and endotoxin. Not offered.
- The 94.6% result, unexplained.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-06 | Janoshik | Semaglutide 20 mg | 97.3% | 96.5% | 81% |
| 2026-03 | Medutest | Retatrutide 5 mg | 98.1% | 97.1% | not tested |
| 2026-02 | PeptideMeter | Retatrutide 15 mg | 97.4% | 96.7% | 78% |
| 2025-11 | Medutest | Tesamorelin 15 mg | 96.3% | 95.5% | 83% |
| 2025-08 | VendorInvestigate | Semaglutide 20 mg | 97.2% | 95.7% | not tested |
| 2025-04 | Janoshik | Retatrutide 20 mg | 96.7% | 95.7% | 83% |
| 2025-02 | VendorInvestigate | Survodutide 15 mg | 97.2% | 96.1% | not tested |
| 2024-12 | VendorInvestigate | Tesamorelin 10 mg | 97.0% | 96.0% | not tested |
| 2024-10 | Janoshik | Survodutide 15 mg | 96.2% | 95.1% | not tested |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 0 of 8 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2026-05 | Requested the reference-standard lot number | Declined as commercially confidential |
| 2026-04 | Asked for the name of the synthesis facility | No response after two follow-ups |
| 2025-11 | Asked whether sterility or endotoxin testing is performed | No response after two follow-ups |
| 2025-01 | Asked whether release testing is performed per lot or per campaign | Answered in part; the specific question was not addressed |
| 2024-12 | Asked whether corrected certificates are reissued to earlier purchasers | Answered in part; the specific question was not addressed |
| 2024-05 | Requested the counter-ion form and residual solvent data | Answered in part; the specific question was not addressed |
| 2024-05 | Asked which catalogue items are synthesised in-house | Answered with a restatement of published quality claims |
| 2024-04 | Asked whether pre-change stock remained in distribution | Answered in part; the specific question was not addressed |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Solid on the BPC-157 5 mg. Purity where it should be, transit 5 days, paperwork in order.
Weighed 6 vials from the glutathione 600 mg order against label. Every one inside 2% of stated mass. Fill consistency is harder than purity and they have it.
Lot code on the vial matched the lot code on the certificate exactly. Sounds basic; it is the single best predictor of everything else.
Certificate claimed 98.4% on lot HOM-26-914. VendorInvestigate came back 98.8%. On an independent column that is as close to agreement as this gets.
First order, deliberately small, hexarelin 5 mg only. Documentation, transit and a Janoshik result at 99.7% all checked out, so the next one will not be small.
VendorInvestigate has now seen 3 of their lots through me. Not one has come back outside spec.
Queried the related-substances total on lot HOM-24-693; they came back with method, column and detection limit. That depth is rare.
Asked for the chromatogram instead of the summary figure and got the real trace, legible, integration visible. They send it without hesitating.
6 lots logged now, purity 98.4 to 98.6%. A band that tight is worth more to me than one spectacular number.
Same lot documentation as the factory ships, but out of their warehouse in Germany, so it landed on day 3.
Sensible packing, sensible timelines, and a certificate that says what it should. No notes.
Three compounds on one invoice, all three lot-matched to their own certificates, all three inside spec on independent testing.
Quoted 4 days, arrived in 4. Tracking updated at every hop from dispatch to door.
Good communication throughout, accurate lead time, and the parcel arrived on day 5.
Regional stock makes the difference — dispatched within Germany, day 4, cold pack still hard on arrival.
Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.
One of the few places that will quote selank 10 mg at all, and the synthesis came back clean on an independent check.
They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.
Reordered on the strength of the last one and got an identical result. Repeatability is the product.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
The certificate for lot HOM-25-993 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.
Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 6 hours.
Their raw material tested 99.4% against a reseller vial of nominally the same compound at 99.3%. Going direct is the whole argument.
Ordered on a Monday from their warehouse in the Netherlands and it was here by day 4. That is the whole case for regional stock.
Fourth order from them, all BPC-157 5 mg. Sent one vial from each to Janoshik and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.
Moved here after two bad lots elsewhere. 4 orders in and the VendorInvestigate numbers have been flat every single time.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from homopeptide.net. Visit Homopeptide → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Hunan Aslsen Technology Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.